openPR Logo
Press release

ENCITE Symposium ”Red hot MRI: In vivo 19F imaging” Towards clinical application

11-29-2012 07:56 PM CET | Health & Medicine

Press release from: EIBIR GmbH

Press Article Nijmegen

Press Article Nijmegen

Nijmegen, The Netherlands, October 29, 2012: The European Network for Cell Imaging and Tracking Expertise (ENCITE) held a 2-day symposium at the Radboud University Nijmegen Medical Centre (NL) on October 25-26, 2012 on the emerging technique of fluorine (19F) Magnetic Resonance Imaging (MRI), titled "Red hot MRI: In vivo 19F imaging".

19F MRI is uniquely applicable to areas such as cell tracking. This has yet to be applied in the clinic, although clinical trials are ongoing. The field has made tremendous progress since its first demonstration in 2005, in a paper in Nature Biotechnology. Since that time, several research groups throughout Europe have been working on this issue. In particular, the following research organisations within the ENCITE consortium have been closely collaborating on this for three years now: Max-Planck-Institute for neurological science (DE), Westfälische Wilhelmsuniversität Münster (DE), Katholieke Universiteit Leuven (BE), Leiden University Medical Center (NL) and Erasmus MC (NL). Thus, this symposium was organised to bring together researchers interested in 19F MRI, and provide an informal platform for discussing the technique and problems encountered.

The first day of the meeting was open to all scientists, and the second was for ENCITE members only. This was the first meeting of its kind in the Netherlands. The programme included invited keynote talks and abstract presentations. A wide range of topics were presented, such as chemical syntheses of novel probes, design and optimisation of imaging sequences, cell labelling and hardware development.
In total, more than 50 registrants and 15 abstract submissions were received from Europe, mainly from The Netherlands, Germany, Belgium and Italy. Abstracts were received from both academia and industry. The format of the meeting allowed plenty of time for questions and answers as well as fruitful discussions, and the participants responded enthusiastically. The symposium was endorsed by the European Society of Magnetic Resonance in Medicine and Biology (ESMRMB).

Due to the success of the meeting, it is planned to organise this workshop on a regular basis.

Details on the latest news: www.encite.org

For further information on the project please contact:
European Institute for Biomedical Imaging Research (EIBIR), Project Coordination
Neutorgasse 9, 1010 Vienna (AT)
Phone: +43-1-5334064-20 / office@eibir.org / www.eibir.org, www.encite.org

Scientific Coordinator: Prof. Gabriel P. Krestin, ERASMUS MC, ehaas@eibir.org
###

EIBIR - European Institute for Biomedical Imaging Research
Website: www.eibir.org
Contact: office@eibir.org

EIBIR gemeinnützige GmbH
zur Förderung der Erforschung der biomedizinischen Bildgebung
Neutorgasse 9, 1010 Vienna, Austria
T +43 1 533 40 64-20, F +43 1 535 70 41
www.eibir.org
office@eibir.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ENCITE Symposium ”Red hot MRI: In vivo 19F imaging” Towards clinical application here

News-ID: 244239 • Views: 1510

More Releases from EIBIR GmbH

Living cells as an "active drug" Advances in image-guided cell therapy promise b …
Leiden, Austria, November 19, 2012 - A video showcasing how in vivo image-guided cell therapy is revolutionising medicine and describing ENCITE’s strong contribution to this revolution has been launched at the ENCITE’s workshop “on cell imaging and tracking: now and the future” at the Leiden University Medical Centre/NL on November 5, 2012. For three patients, each affected by one of today’s major health care problems – diabetes, cancer and cardiovascular disease
ENCITE hands-on workshop “Cell tracking with MRI“ The method of choice for p …
Cologne, Germany, November 14, 2012: Within the framework of the European Network for Cell Imaging and Tracking Expertise (ENCITE) the In-vivo-NMR laboratory at the Max-Planck-Institute for Neurological Research (DE) invited to a 3-day hands-on workshop on November 7-9, 2012, kindly supported by the companies Miltenyi Biotec, Viscover and Medres. The workshop was dedicated to elucidate the techniques and methods necessary for MRI based cell tracking with a focus on neuroimaging.
Cell imaging and tracking: now and the future Promising methods developed to pla …
Vienna, Austria, November 12, 2012 – The European Network for Cell Imaging and Tracking Expertise (ENCITE) held its final workshop on cell imaging and tracking at the Leiden University Medical Centre/NL, on November 5, 2012, attracting over 100 participants. In addressing the questions “What are the clinical needs for imaging and improved disease diagnosis?” and “What are the best tools for translation to clinic?” ENCITE has achieved promising advances, some

All 4 Releases


More Releases for Nijmegen

Stakeholders agree on what is needed to improve the care of patients with myelod …
Nijmegen, 17 August 2017 – More than 70 leading medical specialists, nurses, patient advocates, researchers, regulatory / Health Technology Assessment (HTA) experts and industry representatives gathered on 3 May 2017 in Valencia, Spain to discuss existing challenges and what is needed to improve the situation of patients affected by myelodysplastic syndromes (MDS). More and better research data, additional and improved clinical trials and treatment options, better professional guidance and enhanced
Global Smoke Extraction Motors Market Research Report 2017-2022 ABB, Mitsubishi …
Smoke Extraction Motors Market Research Report A market study based on the " Smoke Extraction Motors Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Smoke Extraction Motors Market 2017’. The research report analyses the historical as well as present performance of the worldwide Smoke Extraction Motors industry, and makes predictions on the future status of Smoke Extraction Motors market on the basis
ANVISA approval for EMCM facilitates the progress of Leader Biomedical operation …
6 April 2017- AMSTERDAM/SAO PAULO- Leader Biomedical is proud to announce that our manufacturing facility in Nijmegen, European Medical Contract Manufacturing B.V. (EMCM) has received approval by the Brazilian competent authority, Agência Nacional de Vigilância Sanitária (ANVISA). This approval follows the previously announced, ANVISA approval of our facilities in Brazil, Inovações Biológicas Comercial LTDA (Leader Biomedical Brazil), which validated the warehouse facilities and presence of technical staff, ensuring quality standards
Lead Pharma Achieves Second Milestone for Development of Autoimmune Diseases Tre …
-- Company receives undisclosed second milestone payment -- Nijmegen, February 27, 2017 – Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has achieved a second milestone under its research collaboration with Sanofi, triggering an undisclosed milestone payment. The collaboration aims to develop small molecules directed against the nuclear hormone receptor ROR gamma (t) for the treatment of a broad
Cell imaging and tracking: now and the future Promising methods developed to pla …
Vienna, Austria, November 12, 2012 – The European Network for Cell Imaging and Tracking Expertise (ENCITE) held its final workshop on cell imaging and tracking at the Leiden University Medical Centre/NL, on November 5, 2012, attracting over 100 participants. In addressing the questions “What are the clinical needs for imaging and improved disease diagnosis?” and “What are the best tools for translation to clinic?” ENCITE has achieved promising advances, some
Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem update on drug develop …
Bielefeld, Germany & Nijmegen, the Netherlands – 14 March 2012. Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem have reached important milestones in two drug development collaborations. In both projects in vivo proof of concept has been shown, moreover in one of them a preclinical candidate has been nominated. The development projects involve novel classes of molecules with potential use in dermatology. ‘We are of course very glad we